Last reviewed · How we verify
PK101
PK101 is a small molecule that targets the SGLT2 receptor.
PK101 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | PK101 |
|---|---|
| Sponsor | PMG Pharm Co., Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, PK101 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis (PHASE3)
- Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs (PHASE1)
- Drug-Drug Interaction Between PK101-001 and PK101-002 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PK101 CI brief — competitive landscape report
- PK101 updates RSS · CI watch RSS
- PMG Pharm Co., Ltd portfolio CI